RBC Capital raised the firm’s price target on Vertex Pharmaceuticals (VRTX) to $420 from $408 and keeps a Sector Perform rating on the shares.

KING OF PRUSSIA, Pa., March 11, 2025 (GLOBE NEWSWIRE) -- Vertex, Inc. (NASDAQ: VERX) today announced that it will host an Investor Day on Wednesday, March 19, in Philadelphia, PA. The event will ...

Vertex Pharmaceuticals generated more than $11 billion in product revenue last year thanks to its dominance in cystic fibrosis treatment. Progress in that specialty area and two key drug approvals ...

From its origins in a garage to becoming one of the most recognisable symbols in the world, explore the story behind the iconic Apple logo design. Apple is a company that has changed the technology ...

Albania's Minister of Education confirmed the prime minister's previous announcement of a year-long ban on social media site TikTok, saying that it will be imposed within days. Photo illustration ...

Journavx works differently than other available medications, and its developer, the biotechnology juggernaut Vertex Pharmaceuticals, has positioned it as an important, non-opioid option for pain ...

Some opposition MPs lit flares and threw smoke bombs during a parliament session - the first since mass protests claimed the resignation of the Serbian prime minister. Smoke bombs in the Serbian ...